Acquisition is highlighted by eneboparatide, Amolyt’s Phase III peptide for hypoparathyroidism with a novel mechanism of action.
![AstraZeneca Acquires Amolyt Pharma with the Aim of Developing Rare Endocrine Disease Treatments](https://onclive.s3.amazonaws.com/onclive_630x1200.png)
Acquisition is highlighted by eneboparatide, Amolyt’s Phase III peptide for hypoparathyroidism with a novel mechanism of action.